110 related articles for article (PubMed ID: 16007188)
1. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Barnes DJ; Schultheis B; Adedeji S; Melo JV
Oncogene; 2005 Sep; 24(42):6432-40. PubMed ID: 16007188
[TBL] [Abstract][Full Text] [Related]
2. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
3. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
4. Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
Campanini F; Santucci MA; Pattachini L; Brusa G; Piccioli M; Barbieri E; Babini L; Tura S
Haematologica; 2001 Feb; 86(2):167-73. PubMed ID: 11224486
[TBL] [Abstract][Full Text] [Related]
5. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
7. Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Cambier N; Zhang Y; Vairo G; Kosmopoulos K; Metcalf D; Nicola NA; Elefanty AG
Oncogene; 1999 Jan; 18(2):343-52. PubMed ID: 9927191
[TBL] [Abstract][Full Text] [Related]
8. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
11. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
12. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
13. BCR/ABL expression of myeloid progenitors increases beta1-integrin mediated adhesion to stromal cells.
Fierro FA; Taubenberger A; Puech PH; Ehninger G; Bornhauser M; Muller DJ; Illmer T
J Mol Biol; 2008 Apr; 377(4):1082-93. PubMed ID: 18313694
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.
Simanovsky M; Berlinsky S; Sinai P; Leiba M; Nagler A; Galski H
Differentiation; 2008 Oct; 76(8):908-22. PubMed ID: 18452548
[TBL] [Abstract][Full Text] [Related]
16. Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Gutiérrez-Berzal J; Castellano E; Martín-Encabo S; Gutiérrez-Cianca N; Hernández JM; Santos E; Guerrero C
Exp Cell Res; 2006 Apr; 312(6):938-48. PubMed ID: 16443220
[TBL] [Abstract][Full Text] [Related]
17. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
18. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
[TBL] [Abstract][Full Text] [Related]
19. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
Cambier N; Chopra R; Strasser A; Metcalf D; Elefanty AG
Oncogene; 1998 Jan; 16(3):335-48. PubMed ID: 9467959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]